The Service Line

Who’s Buying: Atrium Health and OrthoCarolina deepen ties, launch ASC joint venture

Atrium Health and OrthoCarolina announced on July 13, 2026 an expanded clinical affiliation, aligning Atrium’s Musculoskeletal Institute with OrthoCarolina, one of the largest independent orthopedic groups in the country, and creating a new ambulatory surgery center joint venture to move more procedures into lower-cost outpatient settings. OrthoCarolina stays physician-owned and physician-led, and the release is explicit that Atrium is not taking an equity stake, a structure other systems chasing ortho volume without a straight acquisition will study closely. The deal lands in greater Charlotte, keeping this issue’s state-level coverage in North Carolina rather than the usual Florida default. Source: Atrium Health newsroom, supplemented by Becker’s Spine Review.

Reimbursement: CMS proposes folding more spinal fusion into mandatory TEAM bundles

The fiscal year 2027 Inpatient Prospective Payment System proposed rule, published April 10, 2026, would add three new spinal fusion MS-DRGs (523, 524, 525) and expand the mandatory Transforming Episode Accountability Model to cover them, on top of the lower-extremity joint replacement and hip fracture episodes already live since January 1, 2026 in 188 selected core-based statistical areas. The comment period closed June 9, 2026, and CMS typically finalizes IPPS rules by early August for an October 1 start, so hospitals and their affiliated spine surgeons in TEAM markets have roughly three weeks to model episode target-price exposure for fusion cases before the policy is locked in. Confidence: Medium on the exact finalization date, high on the substance of the proposal. Source: CMS FY 2027 IPPS proposed rule home page.

Enforcement: spine device kickback pipeline keeps producing guilty pleas, knee implant maker pays $38.5 million

Aditya Humad, former chief financial officer of spinal device company SpineFrontier, pleaded guilty on May 12, 2026 to conspiring to pay more than $540,000 in kickbacks to surgeons disguised as consulting fees, with sentencing set for August 6, 2026, the latest in a Massachusetts-based prosecution line that has already produced settlements from individual surgeons in New York, Ohio, Maryland, and Florida. Separately, knee implant maker Aesculap Implant Systems agreed in November 2025 to pay $38.5 million and entered a non-prosecution agreement after the government alleged the company knew its VEGA System Knee System failed at an elevated rate for 13 years without disclosing it to physicians or hospitals, a device-defect theory of False Claims Act liability that operators should watch as distinct from the more familiar physician-owned-distributorship kickback cases. Sources: Becker’s Spine Review, CFO guilty plea, citing the underlying DOJ charging document, and DOJ/OIG press release, Aesculap settlement.

Who’s Buying: independent physical therapy platforms keep rolling up, multiples hold at 8 to 12x

Orthopedic and Balance Therapy Specialists, a seven-location outpatient physical therapy provider in Northwest Indiana founded in 2003, sold to an unnamed national rehabilitation platform in a deal completed the week of July 6, 2026 with undisclosed terms, continuing the pattern of founder-owned multi-clinic PT groups being absorbed by scaled platforms. Stout’s 2026 industry outlook puts quality orthopedic and ancillary platform multiples at roughly 8 to 12x EBITDA, with ASC ownership adding a turn, and describes deal volume as robust heading into the back half of the year even as ortho has so far avoided the FTC rollup scrutiny hitting other specialties. Confidence: Medium on multiples, which come from sell-side and banker sources with an interest in showing strong pricing. Sources: Lawrence, Evans & Co. deal update, July 13, 2026 and Stout 2026 Industry Outlook: Orthopedic Practices and Ancillary Services.

Clinical Policy: prior authorization denials for spine surgery keep getting reversed, and payers now have to say why

Research presented at the AAOS 2026 Annual Meeting found that prior authorization delayed elective spine surgery without producing cost savings for payers, and that 80 percent of the claim denials examined were ultimately reversed on appeal, evidence AAOS is using to press for federal prior-auth reform. That study lands alongside CMS-0057-F, effective January 1, 2026, which now requires Medicare Advantage and other CMS-regulated payers to give a specific reason for every prior authorization denial rather than a boilerplate rejection, a change that gives practices firmer ground to appeal. Source: AAOS 2026 Annual Meeting press kit.

The Operator Metric: your prior authorization appeal rate

The number to track this week is 80 percent, the share of orthopedic prior authorization denials that get overturned on appeal per the AAOS-presented spine surgery analysis above. Practices that treat a Medicare Advantage or commercial denial as final rather than provisional are leaving covered, medically necessary cases on the table. If your practice’s internal appeal rate on musculoskeletal denials is meaningfully below 80 percent, that is a workflow problem, not a payer-policy problem. Source: AAOS 2026 Annual Meeting press kit.